We provide you with 20 years of free, institutional-grade data for MLYS stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of MLYS. Explore the full financial landscape of MLYS stock.
| Reported Date | CIK | Ticker | Type | |
|---|---|---|---|---|
| 2025-08-12 | 1933414 | MLYS | 10-Q | Url |
| 2025-05-12 | 1933414 | MLYS | 10-Q | Url |
| 2025-02-12 | 1933414 | MLYS | 10-K | Url |
| 2024-11-12 | 1933414 | MLYS | 10-Q | Url |
| 2024-08-13 | 1933414 | MLYS | 10-Q | Url |
| 2024-05-09 | 1933414 | MLYS | 10-Q | Url |
| 2024-03-21 | 1933414 | MLYS | 10-K | Url |
| 2023-11-07 | 1933414 | MLYS | 10-Q | Url |
| 2023-08-07 | 1933414 | MLYS | 10-Q | Url |
| 2023-05-15 | 1933414 | MLYS | 10-Q | Url |
| 2023-03-15 | 1933414 | MLYS | 10-K | Url |
| 2023-01-18 | 1933414 | MLYS | S-1 | Url |
Mineralys Therapeutics, Inc.(NASDAQ:MLYS) 
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase in...
Website: https://mineralystx.com
Founded: 2019
IPO Price: $16 (Feb 10, 2023)
CEO: Jon Congleton
Sector: Healthcare
Industry: Biotechnology
Share this website to your friends
The information provided in this report about MLYS stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.